The Episcan will be used as part of the facilities’s admission process and for regular ongoing skin assessment protocols. Installation of the units is expected to commence in approximately one month. Longport has been conducting a study with the purchasing group, and the impressive results have led them to make this purchase.
Karen Zulkowski, principal investigator of Episcan study, said: “Study results demonstrated that 90% of people come into a nursing home with deep tissue skin changes at their heels and 60% have deep tissue changes at their sacrum. The Episcan I-200 shows these changes even before they are visible at the skin surface. This technology will allow the facilities to begin care planning earlier and increase quality of care for their residents.”